Clinical Observation of Different Dose of Ambroxol in the Treatment of Diabetes Complicating with Community-acquired Pneumonia

OBJECTIVE:To observe clinical efficacy and safety of different dose of ambroxol in the treatment of diabetes complicating with community-acquired pneumonia(CAP). METHODS:70 patients with diabetes complicating with CAP were randomly divided into routine dose group and double dose group. Both groups were given hypoglycemic drugs orally,intramuscular injection of insulin and other routine treatment. Routine dose group was additionally given Ambroxol oral solution 10 ml,bid,moxifloxacin hydrochloride 0.4 g added into 0.9% Sodium chloride injection 250 ml,i.v.,qd. Double dose group additionally received Ambroxol oral solution 20 ml,bid,moxifloxacin hydrochloride(same usage and dosage as routine dose group). Treatment course of 2 groups lasted for 7 d. Clinical efficacies of 2 groups were observed,and total symptom score,blood glucose and ADR were also observed before and after treatment. RESULTS:Total effective rate of double dose group was significantly higher than that of routine dose group;there was statistical significance(P0.05). Total symptom score of 2 groups had no statistical significance before treatment(P0.05). Total symptom scores of 2 groups after treatment were significantly lower than before;the double dose group was lower than the routine dose group;there was statistical significance(P0.05). There was no statistical significance in blood glucose and the incidence of ADR in 2 groups before and after treatment(P0.05). CONCLUSIONS:Therapeutic efficacy of double dose of ambroxol is significantly better than routine dose in the treatment of diabetes complicating with CAP and also has better safety.